High-yield points
- Chordoma is rare in children (under 5%), mostly cranial, with more metastases at presentation but longer survival than adults .
- Worse prognosis:
- under 10 years;
- dedifferentiated, chondroid or poorly differentiated (INI1-lost) histology .
- TSC-associated chordoma: infants, often sacral; 3 of 4 sacral cases were alive and tumor-free .
- Treatment:
- maximal safe resection (GTR or en bloc where feasible), then high-dose protons (about 70–75 Gy(RBE)) ;
- biopsy alone does worse .
- Conventional pediatric spinal chordoma after surgery and protons: about 94% overall survival at 20 years .
- Chondrosarcoma: off-midline petroclival; after surgery (mostly subtotal) plus protons, 10-year overall survival was about 93% across the whole cohort .
Chordoma arises from notochordal remnants. It is rare in children: fewer than 5% of chordomas occur in childhood .
- Behavior: locally aggressive, with a high local recurrence rate.
- Metastasis: 40–60% of patients develop metastases over the course of the disease .
Chondrosarcoma is a cartilaginous malignancy that mimics chordoma at the skull base, but typically arises off the midline.
Both are treated the same way :
- at an experienced multidisciplinary center;
- maximal safe resection;
- then high-dose, highly conformal radiotherapy, usually protons.
Chordoma in children: what's different
- Population data (SEER, 86 children aged 19 or under vs 1,272 adults) :
- children's chordomas are most often cranial and usually under 4 cm;
- more distant disease at presentation in children (14.8% vs 9.2%);
- yet longer overall survival (17.2 vs 12.6 years);
- surgery significantly improved survival, and the authors recommend it as first-line in all eligible children.
- Head and neck chordomas (SEER, 141 children) :
- 84.4% at the skull base; 85.8% conventional histology;
- age under 10 years was associated with worse survival;
- dedifferentiated histology (more common under 10) and chondroid histology (more common at 10 or older) carried worse cancer-specific survival;
- definitive chemotherapy was a marker of worse outcome.
- Tuberous sclerosis link :
- TSC-associated childhood chordomas present far earlier: median 6.2 months vs 12.5 years in the general pediatric population;
- they are more often sacral (40% vs 9.4%), often fetal or neonatal;
- and did well: 3 of 4 sacral cases were alive and tumor-free.
- Poorly differentiated chordoma :
- occurs in younger children, usually at the clivus;
- shows loss of SMARCB1 (INI1), mostly by deletion, and stays brachyury-positive;
- has a worse prognosis than conventional chordoma and a distinct methylation profile.
Diagnosis
- MRI: a T2-bright, lobulated, destructive midline mass. CT shows the bone destruction (see caveats).
- Pathology:
- brachyury (nuclear) positivity confirms chordoma and separates it from chondrosarcoma (see caveats);
- check INI1 in young children .
- Biopsy: plan any biopsy so that its track can be removed at definitive surgery. Avoid contaminating new compartments, especially in the spine and sacrum (see caveats).
Skull base chordoma
- Pediatric clival chordoma (31 patients, mean age 10.7) :
- abducens palsy was the commonest symptom;
- tumors were large and spanned several compartments;
- gross total resection plus proton therapy: GTR gave better progression-free and overall survival;
- Collins' law: children who passed the period of risk without progression were far more likely to stay progression-free (OR 16).
- Pediatric and adolescent series (62 of 516 skull base chordomas, 12%) :
- most often at the craniocervical junction (41.8%), where GTR was hardest;
- complications: endoscopic 22.7% vs open 57.9%;
- GTR predicted better survival.
- Approach: endoscopic endonasal for midline clival disease; open or combined approaches for lateral or craniocervical extension.
- Craniocervical junction disease may need occipitocervical fusion (see caveats).
Spinal and sacral chordoma and chondrosarcoma
- Pediatric spinal chordoma and chondrosarcoma after proton therapy (52 patients aged 22 or under, 1989–2019) :
- sites: cervical spine 71%, thoracic 12%, lumbar 14%, sacrum 3%;
- pathology: 43 chordomas (10 atypical or poorly differentiated) and 9 chondrosarcomas (4 mesenchymal);
- dose: median 74.5 Gy(RBE) after surgery;
- 20-year survival: overall 72.3%. For conventional chordoma: 93.9% overall, 87.9% progression-free;
- recurrence in 32.7% (8 local, 7 distant, 2 iatrogenic);
- worse outcomes with:
- poorly differentiated subtype;
- chemotherapy before radiotherapy;
- low performance status.
- Progression before radiotherapy predicted worse progression-free survival.
- Late grade 3 toxicity occurred in 2.
- Surgery:
- en bloc resection with negative margins is the goal where feasible, especially in the sacrum and mobile spine ;
- intralesional piecemeal resection risks local recurrence and seeding (see caveats);
- instrumentation and reconstruction are planned around radiotherapy.
- Children are different: consider growth, spinal stability and fusion across growing segments.
Chondrosarcoma
- Where: usually off midline at the petroclival synchondrosis, unlike midline chordoma (see caveats).
- Skull base chondrosarcoma, proton-based radiotherapy (84 patients aged 22 or under, MGH) :
- surgery before radiotherapy: gross total in 11%, subtotal in 76%;
- median 70 Gy(RBE);
- 10-year overall survival 93.3%, progression-free survival 88%;
- worse with mesenchymal histology and progression before radiation;
- late grade 3 or higher toxicity in 9.9%.
- Implication: maximal safe resection, then high-dose protons. Radical resection at any cost isn't necessary.
Radiotherapy
- Pencil-beam proton therapy (76 children, adolescents and young adults with chordoma or chondrosarcoma; median 73.8 Gy(RBE)) :
- 7-year overall survival 86.3%, local control 87.7%;
- worse with biopsy only versus resection (local control 67.7% vs 87.1%) and with recurrent tumors.
- Doses: in the 70–75 Gy(RBE) range across series .
Related topics
- Tuberous Sclerosis Complex: the TSC link to early-onset chordoma.
- Skull and Skull Base Bone Tumors: other bone tumors of the skull and skull base.
- Primary Bone Tumors of the Pediatric Spine: other primary vertebral tumors.
- Normal Embryological Development of the Brain and Spine: the developmental step behind this lesion.
References
- McMaster ML, Goldstein AM, Parry DM. Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population. J Med Genet 2011;48(7):444–449. doi:10.1136/jmg.2010.085092. PMID 21266383. verified
- Radaelli S, Frezza AM, Fossati P, et al. Global consensus on the management of primary localized chordoma. JAMA Oncol 2026;12(9):1018–1026. doi:10.1001/jamaoncol.2026.2054. PMID 42424068. verified
- Vazquez M, Cherchik A, de Angelis C, et al. Long-term clinical outcome and quality of life of children, adolescents, and young adults with chordoma or chondrosarcoma treated with pencil beam scanning proton therapy. Pediatr Blood Cancer 2025;72(10):e31898. doi:10.1002/pbc.31898. PMID 40682267. verified
- Ioakeim-Ioannidou M, Goldberg S, Urell T, et al. Proton-based radiation therapy for skull base chondrosarcomas in children and adolescents: 40-year experience from the Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2025;121(2):403–413. doi:10.1016/j.ijrobp.2024.09.030. PMID 39303998. verified
- Lau CS, Mahendraraj K, Ward A, Chamberlain RS. Pediatric chordomas: a population-based clinical outcome study involving 86 patients from the Surveillance, Epidemiology, and End Result (SEER) database (1973–2011). Pediatr Neurosurg 2016;51(3):127–136. doi:10.1159/000442990. PMID 26881831. verified
- Clementi EA, Timothee P, Charles-Obi K, et al. Pediatric head and neck chordomas: a national analysis of prognostic indicators and survival outcomes. Otolaryngol Head Neck Surg 2026;174(2):522–530. doi:10.1002/ohn.70066. PMID 41252601. verified
- Duan Z, Feng J, Wang H, et al. Comprehensive profiling of paediatric chordoma: poorly differentiated and conventional subtypes. Brain Commun 2026;8(3):fcag207. doi:10.1093/braincomms/fcag207. PMID 42293322. verified
- Rassi MS, Hulou MM, Almefty K, et al. Pediatric clival chordoma: a curable disease that conforms to Collins' law. Neurosurgery 2018;82(5):652–660. doi:10.1093/neuros/nyx254. PMID 28521059. verified
- Bai J, Zhang S, Zhai Y, et al. A series of 62 skull base chordomas in pediatric and adolescent patients: clinical characteristics, treatments, and outcomes. Neurol India 2020;68(5):1030–1036. doi:10.4103/0028-3886.294548. PMID 33109847. verified
- Ioakeim-Ioannidou M, Niemierko A, Mukhammadov T, et al. Long-term outcomes following proton-based radiation therapy for pediatric chordomas and chondrosarcomas of the mobile spine and the sacrum. Int J Radiat Oncol Biol Phys 2025;123(1):63–73. doi:10.1016/j.ijrobp.2025.03.075. PMID 40204245. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
- References 3, 4, 7, 8 and 9 and their numbers were carried over from the skull tumors topic, where they were previously audited.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- the MRI/CT appearance;
- brachyury separating chordoma from chondrosarcoma;
- biopsy-track planning;
- surgical approaches and occipitocervical fusion;
- en bloc versus intralesional recurrence risk;
- growth considerations;
- the petroclival location of chondrosarcoma.
- Reference 2's abstract states maximal safe surgery and high-dose conformal radiotherapy and site-specific surgical guidance; the en bloc emphasis is a summary of that guidance.
- Reference 3 includes young adults up to age 25; references 4, 8 and 10 include patients up to age 22; reference 5 compares children with adults.
- Reference 9's endoscopic versus open complication comparison is unadjusted.
- The figure is an original schematic.